At Canvax, we are committed to advancing biomanufacturing through the GROWFAC project, an internal R&D initiative focused on the development of scalable, robust, and cost-efficient bioprocesses for the production of recombinant growth factors.
Growth factors are biologically active proteins that regulate essential cellular processes such as proliferation, differentiation, and survival. In the pharmaceutical industry, they serve two major purposes:
- As therapeutic proteins, several recombinant growth factors are directly used as active ingredients in drug products for indications ranging from tissue regeneration and wound healing to hematopoietic disorders.
- As critical components in culture media, growth factors are indispensable for the expansion and maintenance of mammalian cells used in the production of other therapeutic proteins, such as monoclonal antibodies or viral vectors.
Their dual role—as both therapeutics and enabling tools in upstream bioprocessing—makes growth factors a strategic focus in modern biomanufacturing, where consistency, biological activity, and purity are paramount.
🔬 Key goals of GROWFAC:
- Development of high-yield microbial expression systems.
- Optimization of USP and DSP workflows under GMP-aligned approaches.
- Enhanced purity, stability, and reproducibility of target proteins.
- Streamlined scale-up and tech transfer for industrial implementation.
🌐 Explore Canvax’s recombinant growth factors already available for RUO
💡 With GROWFAC, Canvax strengthens its role as a biotechnology partner of choice for companies seeking reliable, scalable powerful solutions for Biologics Manufacturing enabling safer, more efficient, and cost-effective growth factors for the pharma and biotech sectors.
The GROWFAC project has been funded by the Centre for the Development of Industrial Technology (CDTI) and supported by the Ministry of Science, Innovation and Universities, with funds from the ERDF (European Regional Development Fund), “Europe Feels.”
with a total approved budget of €321,832 and an execution period from December 2023 to November 2025. This funding supports the development of scalable and efficient bioprocesses for the next generation of pharmaceutical-grade recombinant growth factors.
